Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer

Cancer Chemotherapy and Pharmacology
J R MurrenW N Hait

Abstract

Overexpression of P-glycoprotein (P-gp) has been implicated as the mechanism of multidrug resistance (MDR) in a number of human cancers, including carcinoma of the breast. We conducted a clinical trial to determine whether the P-gp inhibitor, trifluoperazine, could sensitize patients with refractory breast cancer to vinblastine chemotherapy. Adult patients with histologically confirmed, refractory, advanced breast cancer were treated with vinblastine at a dose of 1.7 mg/m2 per day by continuous infusion for five consecutive days. Patients who did not respond after two cycles were subsequently treated with vinblastine plus trifluoperazine at a dose of 8 mg twice daily during the five days of chemotherapy. In patients from whom tumor samples were available, the expression of P-gp was determined by immunocytochemistry. Of 35 patients enrolled, 30 were evaluable, 2 of whom (7%) achieved a partial response to vinblastine alone. Among the 16 patients treated with vinblastine plus trifluoperazine there was one response (6%) which lasted 16 weeks. Tumor samples were available from 16 patients, and 14 (87%) were immunoreactive for P-pg. P_pg expression was detected both in the patient who responded to vinblastine plus trifluoperazine an...Continue Reading

Citations

Mar 5, 2004·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Andrzej PołaMasami Kawase
Aug 12, 1998·Obstetrics and Gynecology·A K Sood, R E Buller
Oct 30, 1998·Critical Reviews in Oncology/hematology·M ClynesK Scanlon
Jun 5, 2003·Expert Opinion on Investigational Drugs·Rita NahtaFrancisco J Esteva
Jul 5, 2005·Expert Opinion on Investigational Drugs·J Robert
Aug 30, 2001·Hematology/oncology Clinics of North America·R S DiPaolaM M Rafi
Apr 3, 2012·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Laleh Amiri-KordestaniSusan E Bates
Jun 7, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Joyce C de MelloTiago Rodrigues
Mar 20, 2019·Cancers·Philippe KischelHalima Ouadid-Ahidouch
May 16, 2017·The Journal of Clinical Investigation·Jaya SangodkarGoutham Narla
May 16, 2019·Cellular and Molecular Life Sciences : CMLS·Winnie Fong, Kenneth K W To
Aug 3, 2005·Cancer Research·Karl E Miletti-GonzálezLorna Rodríguez-Rodríguez
Apr 30, 2019·American Journal of Therapeutics·Marissa B SerafinRosmari Hörner
Oct 31, 2003·Journal of Medicinal Chemistry·Jacques Robert, Christian Jarry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.